Welcome to Tracy BioConsulting

MATCRS2cropped2-133x106Tracy BioConsulting, LLC is a specialized biopharmaceutical consulting firm dedicated to helping clients transform research into new medicines. The company was founded by Mark A. Tracy, Ph.D. and supports clients in bridging the knowledge, experience and capability gaps that very often exist as organizations strive to rapidly take biomedical research programs into and through the clinic.

Tracy BioConsulting, LLC provides:

  • Documented success in the development of nucleic acid, protein, peptide, and small molecule based medicines
  • Expertise in developing products incorporating novel drug delivery systems, nanotechnology, and targeting
  • Proven product development know-how and best practices, as well as successful advancement through the regulatory review and approval processes
  • Management and integration of alliance and collaboration partners
  • An extensive network of CROs and CMOs
  • Identification of new business opportunities and creation of value from technology platforms and capabilities

Tracy BioConsulting, LLC welcomes the opportunity to work with you in your quest to advance programs, build capabilities, seek strategic areas of growth for your organization and ultimately develop innovative new medicines for patients.

“As our case is new, we must think and act anew.”  Abraham Lincoln

BioConsulting Briefs
MATCRS2cropped2-133x106
Mark Tracy Receives CRS Distinguished Service Award
Mark A. Tracy was awarded the prestigious Distinguished Service Award of the Controlled Release Soci ( Read More )
MATCRS2cropped2-133x106
Interview with Mark Tracy
Insights into the Biopharmaceutical Industry ( Read More )
home-img
Interspecies information website
This website is an excellent resource for physiological, anatomical and biochemical parameters for a ( Read More )
innerpage-slide
Good review practices for INDs
A helpful new FDA document was recently issued describing the FDA’s good review practices for ( Read More )
home-img
Approval of Kynamro
The January 2013 approval of Kynamro (mipomirsen) marks the first systemically administered antisens ( Read More )